Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Institutes of Health Clinical Center (CC)
With
National Cancer Institute (NCI)
OBJECTIVES:
* To assess the pharmacokinetic and pharmacodynamic profiles of arsenic trioxide in pediatric patients treated on protocol NCI-00-C-0070J.
OUTLINE: Bone marrow or peripheral blood mononuclear cells collected during treatment on NCI-00-C-0070J are assessed for pharmacodynamics studies. Plasma cells collected during treatment are assessed for pharmacokinetics studies. Total arsenic (As), inorganic As forms (AsIII and AsV), and methylated metabolites of As are assessed.
Age
2–21
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Histologically confirmed leukemia or lymphoma refractory to standard curative treatment regimens
* No meningeal leukemia or lymphoma
* No HIV-related lymphoma
* No lymphoproliferative diseases
Received treatment on protocol NCI-00-C-0070J
Bone marrow or peripheral blood and serum samples collected during treatment on NCI-00-C-0070J are available